Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

• Main Authors: Michael Rosenbloom (Author), Terry Barclay (Author), Justin Johnsen (Author), Lauren Erickson (Author), Aleta Svitak (Author), Maria Pyle (Author), William Frey (Author), Leah R. Hanson (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Individuals with Down syndrome are likely to develop clinical and neuropathological brain changes resembling Alzheimer's disease dementia by the ages of 35-40 years. Intranasal insulin is a potential treatment for neurodegenerative disease that has been shown to reduce amylo...